Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the importance of screening, early detection, risk classification, and precision treatment in myeloma. She discusses screening earlier, before symptoms present to detect and treat precursor conditions such as smoldering myeloma, MGUS, and MGIP. Furthermore, she advocates for using cytogenetics to assist in precision treatment and the use of immunotherapy earlier in disease to potentially achieve a better outcome for patients.